Project Grant HT94252410483
Award Date
6/1/24
Completion Date
5/31/26
Dollars Obligated
$303K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada
Similar Awards
The $1,050,767 federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University Health Network (UHN) to investigate therapeutic targeting of genomic instability in triple negative breast cancer. The research will be conducted at UHN's location in Ottawa, Ontario over a 3-year period from September 2023 to September 2026. This funding supports UHN's ongoing biomedical and clinical research...
The University Health Network will receive $611,415 under a three-year Project Grant award from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care. Under this award, the University Health Network will conduct research from August 2022 to August 2025 to identify novel immune evasion tumor immune networks...
The University Health Network will receive $1,419,453 under a Project Grant award from the Department of the Army Medical Command to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. Funded through the Military Medical Research and Development program (CFDA 12.420), this four-year award beginning September 1, 2022 will support applied research investigating medical solutions for neuroblastoma on the battlefield and...
The University Health Network in Ottawa, Canada received a $543,962 USD Project Grant award from the Department of the Army Medical Command on September 15, 2022 through September 14, 2025. The grant supports research investigating JAK/STAT activation and its role in driving CIC-rearranged sarcoma through the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for battlefield care...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
The University of Minnesota will leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors under a $548,892 project grant from the Defense Health Agency. The grant was awarded on August 1, 2023 with a completion date of July 31, 2026. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through...
This $485,597.91 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research at the Universite De Sherbrooke in Canada. The award will fund a 3-year project from August 1, 2024 to July 31, 2027 focused on understanding the "CONTRIBUTION OF ALTERNATIVE SPLICING TO NEUROFIBROMAGENESIS." The research aims to advance scientific knowledge in the area of neurological disorders, which...
The Defense Health Agency awarded a $999,540.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Governing Council of the University of Toronto, operating as the University of Toronto, to examine the link between hippocampal pathology and meningeal inflammation in progressive multiple sclerosis. The research project is scheduled to be completed by Aug 31, 2026. As a leading public research university, the University of Toronto has a history of...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
This Project Grant award for $1,126,685 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports translatome profiling research conducted by the University of British Columbia (UBC) to identify biomarkers and therapeutic targets for prostate cancer. The project aims to leverage UBC's expertise in biomedical research and advanced analytical capabilities to advance the understanding and treatment of prostate cancer, which is an...